SCHEMBL6134855

SCHEMBL6134855

CC(C)n1nc(-c2cnc(N)nc2-c2ccccc2Cl)ccc1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 1/20 0.36
ADORA1 P30542 6/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
EPAS1 Q99814 1/20 0.36
MAPK14 Q16539 3/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
EGFR P00533 1/20 0.35
FGFR1 P11362 1/20 0.35
SRC P12931 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR4 P22455 1/20 0.35
FGFR3 P22607 1/20 0.35
ADORA2A P29274 5/20 0.35
ADORA2B P29275 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134889 0.89 FGFR1 (0.42) ADORA1EGFRFGFR1SRCFGFR2
SCHEMBL6134252 0.88 ADORA2A (0.38) ADORA1LMNATP53KDM4EMAPK14
SCHEMBL6134468 0.87 ADORA2A (0.37) KDM5BADORA1ADORA2AADORA2B
SCHEMBL6134078 0.87 GFER (0.41) ADORA1LMNATP53EGFRSRC
SCHEMBL6133826 0.87 CLK1 (0.36) ADORA1KDM4EFGFR1ADORA2AADORA2B
SCHEMBL6134324 0.85 ADORA1 (0.47) ADORA1ADORA2AADORA2B
SCHEMBL6133855 0.85 ADORA2A (0.48) ADORA1LMNAHSP90AA1HSP90AB1EGFR
SCHEMBL6135805 0.84 ADORA1 (0.37) ADORA1LMNAFGFR1FGFR2FGFR3
SCHEMBL6134941 0.84 CDC7 (0.38) ADORA1ADORA2AADORA2B
SCHEMBL6134188 0.83 LMNA (0.45) ADORA1LMNAKDM4EADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 KDM5B 2880/4885ADORA1 3/4885LMNA 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.